Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session October 4 2025

October 4, 2025 by sjwilliamspa

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session  October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

1:40 – 2:30

AI in Precision Medicine

Dr. Ganhui Lan VP, Data Science & Machine Learning, Genentech

Dr. Xiaoyan Wang Research Professor, Department of Health Policy and Management, Tulane University Chief Scientist, SVP, Intelligent Medical Objects

Dr. Ahmad P. Tafti Assistant Professor, School of Computing and Information,School of Health and Rehabilitation Sciences, University of Pittsburgh Interim Director, Division of Scientific Affairs, Computational Pathology AI Center of Excellence

Jen Gilburg (moderator)Deputy Secretary of Technology and Entrepreneurship, Dept. of Community and Economic Development, Commonwealth of Pennsylvania

• AI will help reduce time for drug development especially in early phase of discovery but eventually help in all phases
• Ganhui: for drug regulators might be more amenable to AI in clinical trials; AI may be used differently by clinicians
• nonprofit in Philadelphia using AI to repurpose drugs (this site has posted on this and article will be included here)
• Ganhui: top challenge of AI in Pharma; rapid evolution of AI and have to have core understanding of your needs and dependencies; realistic view of what can be done; AI has to have iterative learning; also huge vertical challenge meaning how can we allign the use of AI through the healthcare vertical layer chain like clinicians, payers, etc.
• Ganhui sees a challenge for health companies to understand how to use AI in business to technology; AI in AI companies is different need than AI in healthcare companies
• 95% of AI projects not successful because most projects are very discrete use

2:00-2:20

Building Precision Oncology Infrastructure in Low- and Middle-Income Countries

Sewanti Limaye, MD, Director, Medical & Precision Oncology; Director Clinical and Translational Oncology Research, Sir HN Reliance Foundation Hospital & Research Centre, Mumbai, India; Founder, Nova Precision AI; Co-Founder, Iylon Precision Oncology; Co-Chair, Asia Pacific Coalition Against Lung Cancer; Co-Chair,  Asia Pacific Immuno-Oncology; Member,  WIN Consortium

• globally 60 precision initiatives but there really are because many in small countries
• three out of five individuals in India die of cancer
• precision medicine is a must and a hub and spoke model is needed in these places; Italy does this hub and spoke; spokes you enable the small places and bring them into the network so they know how and have access to precision medicine
• in low income countries the challenge starts with biopsy: then diagnosis and biomarker is issue; then treatment decision a problem as they may not have access to molecular tumor boards
• prevention is always a difficult task in LMICs (low income)
• you have ten times more patients in India than in US (triage can be insurmountable)
• ICGA Foundation: Indian Cancer Genome Atlas
• in India mutational frequencies vary with geographical borders like EGFR mutations or KRAS mutations
• genomic landscape of ovarian cancer in India totally different than in TCGA data
• even different pathways are altered in ovarian cancer seen in North America than in India
• MAY mean that biomarker panels need to be adjusted based on countries used in
• the molecular data has to be curated for the India cases to be submitted to a tumor board
• twenty diagnostic tests in market like TruCheck for Indian market; uses liquid biopsy
• they are also tailoring diagnostic and treatment for India getting FDA fast track approvals

2:20-2:40

Co-targeting KIT/PDGRFA and Genomic Integrity in Gastrointestinal Stromal Tumors

Lori Rink, PhD, Associate Professor, Fox Chase Cancer Center

• GIST are most common nesychymal tumor in GI tract
• used to be misdiagnosed; was considered a leimyosarcoma
• very asymptomatic tumors and not good prognosis
• very refractory to genotoxic therapies
• RTK KIT/PDGFRA gain of function mutations
• Gleevec imatinib for unresectable GIST however vast majority of even responders become resistant to therapy and cancer returns
• there is a mutation map for hotspot mutations and sensitivity for gleevec
• however resistance emerged to ripretinib; in ATP binding pocket
• over treatment get a polyclonal resistance
• performed a kinome analysis; Wee1 looked like a potential target
• mouse studies (80 day) showed good efficacy
• avapiritinib ahs some neurotox and used in PDGFRA mut GIST model which is resistant to imitinib
• but if use Wee1 inhibitor with TKI can lower dose of avapiritinib
• cotargeting KIT/PDGFRA and WEE1 increases replicative stress
• they are using PDX models to test these combinations
• combination creates genomic instability

 

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence Applications in Health Care, Artificial Intelligence in CANCER, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Bio-Ethics, BioBanking, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Biological Networks, Biological Networks, Gene Regulation and Evolution, Cancer Genomics, Cancer Informatics, Clinical Diagnostics, Foundations for supporting Science and Education, Gene Regulation, Health Care System by Country, India, Intelligent Information Systems, Machine Learning, Natural Language Processing (NLP), Personalized and Precision Medicine & Genomic Research, Personalized Medicine Coalition, Precision Cancer Medicine, Proteomics, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, tumor microenvironment | Tagged access to care, AI in Healthcare, Artificial Intelligence & Clinical Trials, Artificial Intelligence ( AI), artificial intelligence in drug design, bioethics, Biomarker discovery, biomarker panels, biomarkers panels, cancer centers, cancer consortium, cancer diagnostics, deep learning in drug discovery, Fox Chase Cancer Center, gastrointestinal carcinomas, Genentech, health disparities, healthcare delivery, immunooncology, India, molecular tumor board, Predictive Cancer Biomarkers | Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Late Morning Session Track 1 October 4 2025

October 4, 2025 by sjwilliamspa

Real Time Conference Coverage: Advancing Precision Medicine Conference, Late Morning Session Track 1 October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

SESSION 3

Advances in Precision Oncology:
From Genomics to Targeted Therapies

11:10-11:55

Breaking the Glass Ceiling: Targeting KRAS in Pancreatic Cancer

Michael Pishvaian, MD, Associate Professor, Department of Oncology, Johns Hopkins University

Kim Reiss, MD, Associate Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania

11:55-12:15

Charting the Future of Cancer Care: Precision Oncology and the Power of Genomics

Vivek Subbiah, MD,
Chief, Early-Phase Drug Development, Sarah Cannon Research Institute

12:15-12:35

Molecular Pathology as a Driver of Precision in Urological Cancers

Liang Cheng, MD, Professor and Vice Chair, Translational Research; Director of Anatomic and Molecular Pathology, Department of Pathology and Laboratory Medicine, Brown University Medical School, Lifespan Academic Medical Center

 

12:30-12:40

Non – CME – dSTRIDE™-HR: A Functional Biomarker for In Situ, ‘real-time’ Detection and Quantification of Homologous Recombination Activity.

Magda Kordon-Kiszala, PhD, CEO and co-founder, intoDNA

12:35-12:55

Epigenetic Plasticity and Tumor Evolution: Mechanisms of Resistance in Precision Oncology

Johnathan R. Whetstine, PhD, Director, Cancer Epigenetics Institute, Director, Geonomics Resource, Fox Chase Cancer Center

• Title: Epigenetic plasticity a gatekeeper to generating extrachromosomal DNA amplification and rearrangements
• genetic events in cancer are actually controlled not random as he says
• Fox Chase Cancer Center Epigenetics Institute; 5th year goal to understand epigenetic mechanisms to understand resistance and biomarker development; bring others and break down silos;  they are expanding and hiring and bringing into a network; March 5 2026 5th Annual Symposium Philadelphia Franklin Institute
• DNA amplification is also chromosomal: integrated same locus or different regions or chromosomal duplication
• KDM4A epigenetic demethylase controls transiet site specific DNA re-replication; can have focal control of DNA regions
• you can control regional control of like EGFR amplification
• can use Cy3 to find local regions
• KDM3B inhibitor promotes transiet copy gains in KMT2A/MLL
• EHMT2 is lysine demethylase is a driver of this copy amplification
• this demethylase can change expression locally in one hour.. very fast
• demethylases are very specific for their gene locus they control and so this demethylase only controls MLL gene
• doxorubicin topoisomerase inhibitor can cause LOH in MLL locus and methylase inhibitor can reverse this
• over twenty combinatorial regulators so this field is just budding

11:30-12:30

Companion Diagnostics in Hereditary and Chronic Diseases – Development, Regulatory Approval, and Commercialization – Non-CME Discussion

Huw Ricketts PhD, Senior Director, CLIA Business Development, QIAGEN

Tricia Carrigan, PhD, BC Biosolutions

Arushi Agarwal, MS,  Partner, Health Advances

Melissa Reuter, MS, MBA, Director, Precision Medicine Program Strategy, GSK

• This is a session panel Discussion on the current state of companion diagnostic development, not just in oncology.  Regulatory aspects will be discussed
• Arushi: There are alot of opportunities in non-oncology areas for companion diagnostics, and time to development may be an obstacle
• Huw Rickets:  From a development standpoint most people are not looking at the diagnostic side but more on the therapeutic side.
• Tricia:  There needs to be a shift in oncology drug development world, and pharma sees developing diagnostic is too expensive.
• Meliisa: They try to engage early with the agencies to understand the regulatory landscape; GSK is very strong in their oncology platform but there are gaps in diagnostics and non-oncology programs
• Arushi: seems in Pharma oncology and non-oncology programs seems siloed
• for non-oncology many of the biomarkers may be rare… well under 25% of population
• Huw: Qiagen trying to develop diagnostics for Parkinson’s but those rare genetic diseases are easier to develop
• Arushi: neurodegenerative, NASH, and immuno diseases are big areas where companies are looking to make companion diagnostics
• Huw: kidney  disease is a big focus to develop companion diagnostics for

 

12:30-12:40

Non – CME – dSTRIDE™-HR: A Functional Biomarker for In Situ, ‘real-time’ Detection and Quantification of Homologous Recombination Activity.

Magda Kordon-Kiszala, PhD, CEO and co-founder, intoDNA

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, Clinical & Translational, Clinical Diagnostics, Clinical Genomics, Conference Coverage with Social Media, FDA Regulatory Affairs, Genomic Expression, Genomic Testing: Methodology for Diagnosis, Healthcare costs and reimbursement, KRAS Mutation, Methylation, Personalized and Precision Medicine & Genomic Research, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, TP53 - Germline mutations | Tagged anticancer drug resistance, biomarker panels, biomarker/companion diagnostics, Biomarkers & Medical Diagnostics, chemotherapy resistance, Commercialization, companion diagnostics, DNA methyation, Epigenetics, GlaxoSmithKline, precision oncology, Qiagen | Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025

October 4, 2025 by sjwilliamspa

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

1:00 – 1:50

Lunch & Exhibits

TRACK 1  204BC

TRACK 2  204A

WIN SYMPOSIUM

MULTI-OMICS

1:50-4:05

SESSION 4

From Targets to Trials:
Translating Discovery into Impact

1:50-2:10

Beyond Checkpoint Inhibitors: Targeted Immunotherapeutic Approaches for the Management of Solid Tumors

Matthew Hadfield, DO, Assistant Professor of Medicine, Phase 1 Clinical Trials, Cutaneous Malignancies, The Warren Alpert Medical School of Brown University 

2:10-2:30

Implementing Molecular Profiling in Early Phase Clinical Trials: Precision from Bench to Bedside

Apostolia M. Tsimberidou, MD, PhD, FASCO, FAAAS, Tenured Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer

2:30-2:40

Q&A

Matthew Hadfield, DO, Assistant Professor of Medicine, Phase 1 Clinical Trials, Cutaneous Malignancies, The Warren Alpert Medical School of Brown University 

Apostolia M. Tsimberidou, MD, PhD, FASCO, FAAAS, Tenured Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer

2:40-3:20

Non- CME Session: Venture Philanthropy

Eric Heil, MBA, Managing Partner, Medical Excellence Capital

John Lehr, President & CEO, Parkinson’s Foundation

Dr. Blaine Robinson, PhD, Vice President of the Therapy Acceleration Program (TAP), Blood Cancer United

3:20-4:10

eNSCLC Testing

Kurt A. Schalper, MD, PhD, Associate Professor of Pathology and Medicine (Medical Oncology), Yale School of Medicine; Director Translational Immuno-Oncology Laboratory, Yale Cancer Center

1:50-2:35

Non – CME Session: AI & Digital Pathology

Shruti Mathur, MS, Pharma Diagnostic Strategy Leader, Global Product Strategy (GPS), Genentech

Kimbery Gasaud,MBA, Principal Consultant, JK Life Sciences LLC

Paul Beresford, PhD, PathAI

Keith Wharton, Roche Diagnostics

2:35-3:50

Omics Into the Clinic – The Next Step

CHAIR: Sizun Jiang, PhD, Principal Investigator, Center for Virology & Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School

2:35-2:55

Arutha Kulasinghe, PhD, Associate Professor, Frazer Institute, University of Queensland; Founding Scientific Director, Queensland Spatial Biology Centre

2:55-3:10

Thazin Nwe Aung, MD
Associate Research Scientist in Pathology, Yale University

3:10-3:25

Ritu Mihani, PhD, Associate Director, Product Marketing, Akoya

3:25-3:50

Panel Discussion

CHAIR: Sizun Jiang, PhD, Principal Investigator, Center for Virology & Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School

Laura Dillon, PhD, Senior Director, Partnership Strategy Lead, External R&D and Innovation, AstraZeneca

Jared K. Burks, PhD, Director, Flow Cytometry & Cellular Imaging Core Facility MD, Anderson Cancer Center

Kurt Schalper, MD, PhD, Associate Professor, Pathology & Medical Oncology

Hoifung Poon, PhD, General Manager, Microsoft Research

4:10 – 4:25

Break and Exhibits

TRACK 1  204BC

TRACK 2  204A

WIN SYMPOSIUM

MULTI-OMICS

4:25-6:45

4:25-5:15

Transforming Pediatric Oncology: The Power of Precision Medicine

Giselle L. Sholler, MD, Division Chief, Pediatric Hematology/Oncology/BMT, Penn State Hershey Children’s Hospital; Professor, Pediatrics and Pharmacology; Founder & Chair, Beat Childhood Cancer Consortium

Wei Zhang, PhD, Hanes and Willis Family Professor in Cancer; Director, Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center

Elias Sayour, MD, PhD, Professor, Neurosurgery and Pediatrics;  Assistant Dean,  Clinical Research, UF College of Medicine, Program Co-leader,  UF Health Cancer Center Immuno-Oncology and Microbiome (IOM) Program

Milan Radovich, PhD, Senior Vice President, Chief Scientific Officer, Caris Life Sciences

Pei Wang, PhD, Professor, Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai

Abigail Moore

5:15-5:25

Informing therapy decisions for improved patient care

Ashley Varghese, PharmD, RPh

5:25-5:50

Liquid Biopsies and Resistance Monitoring in Targeted Therapies 

Pashtoon Kasi, MD, MS, Medical Director, GI Medical Oncology, City of Hope

5:50-6:10

Liquid Biopsies in Clinical Practice: Transforming Precision Oncology Through Molecular Monitoring

Hatim Husain, MD, Associate Professor, University of California, San Diego 

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Posted in Personalized and Precision Medicine & Genomic Research, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session | Tagged Advancing Precision Medicine, Cancer, multiomics platforms, oncology, personalized cancer therapy, precision oncology | Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, MidMorning Session Track 1 October 3 2025

October 4, 2025 by sjwilliamspa

Real Time Conference Coverage: Advancing Precision Medicine Conference, MidMorning Session Track 1 October 3 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

0:40 – 11:10

Break and Exhibits

TRACK 1  204BC

TRACK 2  204A

WIN SYMPOSIUM

MULTI-OMICS

11:10 – 1:10

SESSION 2

The Evolution of Precision Oncology:

Integrating MRD, AI, and Beyond

11:10-12:00

Precision Cancer Consortium

Gabriele Allegri, MBA, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

Shruti Mathur, MS, Pharma Diagnostic Strategy Leader, Global Product Strategy (GPS), Genentech

Daryl Pritchard, PhD, Interim President, Personalized Medicine Coalition

Keith T. Flaherty, MD, FAACR, Director of Clinical Research, Massachusetts General Cancer Center; Professor of Medicine, Harvard Medical School;
President-Elect: 2025-2026, American Association for Cancer Research (AACR) 

SESSION 3

The Shifting Landscape:

Tumor Plasticity and Resistance

12:00-12:20

Mathematical and Evolutionary Modeling in Precision Radiation Oncology

Jacob Scott, MD, DPhil, Professor and Staff Physician-Scientist, CWRU School of Medicine and Cleveland Clinic

12:20-12:40

Plasticity and Persistence: The Role of EMT in Cancer Progression and Therapy Resistance

Sendurai A. Mani, PhD, Professor of Pathology and Laboratory Medicine, Brown University; Associate Director of Translational Oncology, Brown University Legorreta Cancer Center

12:40-1:00

Targeting Molecularly Defined Subsets: Challenges in Translational Oncology

Benedito A. Carneiro, MD, MS, Director, Clinical Research
Director, Cancer Drug Development; Associate Director, Division of Hematology/Oncology
Legorreta Cancer Center, Brown University Health

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Posted in REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage | Tagged multiomics platforms, precision medicine | Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Early Morning Session Track 1 October 4 2025

October 4, 2025 by sjwilliamspa

Real Time Conference Coverage: Advancing Precision Medicine Conference, Early Morning Session Track 1 October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

 

8:55 – 10:35

SESSION 1

Precision For All:

Global Access, Real Cases, and Implementation Science

 

8:55-9:15

Results and Future Direction from WIN’s Data Science Paper

Gerald Batist, MD, Director, Segal Cancer Centre, Jewish General Hospital; Director, McGill Centre for Translational Research in Cancer; Professor, Department of Oncology, McGill University

9:15-9:55

When Precision Gets Personal: WIN Consortium International Molecular Tumor Board Live

Wafik S. El-Deiry, MD, PhD, FACP, Chair, WIN Consortium, Director, Legorreta Cancer Center Brown University, Director, Joint Program in Cancer Biology, Brown University and Brown University Health; Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University; Attending Physician, Hematology/Oncology, Brown University Health Mencoff Family University; Professor of Medical Science, Professor of Pathology and Laboratory Medicine, Brown University; Professor, American Cancer Society Research Professor

Razelle Kurzrock, MD, FACP, Chief Medical Officer, WIN Consortium; Professor of Medicine, Associate Director, Clinical Research, Linda T. and John A. Mellowes Endowed Chair of Precision Oncology, MCW Cancer Center and Linda T. & John A. Mellowes Center for Genomic Sciences and Precision Medicine

Notes from Live Tumor Board from Live Tweets

Tumor board Live… Molecular profiling great for identifying synthetic lethal combinations work very well… Many oncologist not accepting recommendations of molec tumor board

@AVIVA1950

@Pharma_BI

@AdvancingPM

Tumor board Live . Oncologists don’t always accept tumor board recommendations based on molecular profiling… Dr Baptiste at first felt constrained to use single agent but WINTER combo trial with molec profiling better

@Pharma_BI

Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

@Pharma_BI

@AVIVA1950

@AdvancingPM

Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

@Pharma_BI

@AVIVA1950

@AdvancingPM

Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

@Pharma_BI

@AVIVA1950

@AdvancingPM

Pemetrexemed not always working but MTAP inhibitions may work

@Pharma_BI

@AVIVA1950

@AdvancingPM

Tumor board Live… Discussion of ovarian cancer case women first presented with CRC BRCA mut but failed PARP inhibitor board is looking at immunotherapy NGS IHC performed

@Pharma_BI

@AdvancingPM

#WINconsortium

Fusions being detected by RNAseq at rate of 100 per month

@AVIVA1950

@Pharma_BI

@AdvancingPM

Tumor board Live…. Theranostics are becoming part of molec tumor board … Radio labeled dual diagnostic therapeutic antibodies

@Pharma_BI

@AVIVA1950

@AdvancingPM

Tumor board Live… Molecular profiling great for identifying synthetic lethal combinations work very well… Many oncologist not accepting recommendations of molec tumor board

@AVIVA1950

@Pharma_BI

@AdvancingPM

SESSION 2

Expanding the Precision Frontier

9:55-10:25

Precision Oncology in the Immunotherapy Era: Biomarkers and Clinical Trial Innovation

Lillian Siu, MD, President, AACR 2025-2026; Director, Phase I Clinical Trials Program; Co-Director, Robert and Maggie Bras and Family Drug Development Program Clinical Lead, Tumor Immunotherapy Program; BMO Chair, Precision Cancer Genomics, Princess Margaret Cancer Centre Professor of Medicine, University of Toronto

• Princess Margaret CC went to Merck got pembrolizumab from them but built a team platform of clinicians and scientists to work on INSPIRE trial
• $11 million of grants, 13 major papers, great team science
• did ctDNA from liquid biopsy and also looked at methylation patterns in cfDNA
• looked at IFN stimulation and outcome to pembrolizumab
• retro transposable elements found in INSPIRE program, maybe a predictor of immune sensitivity
• they were able to correlate some of their findings with spatial omics
• using spatial data they could look at hot versus cold head and neck cancer
•  factors for response to immunotherapy: TMB, t cell infiltrate,  PDL1 etc
• using AI with IHC slides as well as NGS data sets
• as clinical trials become multiomics and AI with multiomics platforms data sharing will be critical for success

10:25 – 10:35

The Microbiome and Its Role in Cancer Development and Treatment Response

Sabine Hazan, MD, CEO, Ventura Clinical Trials; CEO, Progenabiome

• microbiome research at the infancy so we don’t know much when comes to oncology
• we need to compare microbiome between persons using NGS and other omics
• we all have different microbiome even though microbiome ‘healthy’
• lots of factors affect microbiome including surgery
• families are similar in their microbiome but when looking at Alzheimers there are differences
• first lab to find whole COVID in the stools
• virus was different in different people, difference spike proteins. Virus mutates from lung to stool (gut)
• in intrafamily patients had different microbiome upon COVID infection
• bifodobacteria was found as a major part of microbiome altered in COVID but also lots of other diseases
• lots of examples of host microbial symbiosis
• they had an instance with throat tumor treated with microbiome and tumor receded without chemo
• in a glioblastoma microbiome adjustment helped but changed positive response to immunotherapy

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Posted in Anti-tumor necrosis factor drugs (TNF inhibitors), BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Cancer Genomics, Cancer Informatics, Cancer-Immune Interactions, Circulating Tumor Cells (CTC), Clinical Genomics, COVID-19, Evidence-based decision-making, Genomic Expression, Immuno-Oncology & Genomics, Immunotherapy, Inflammasome, KRAS Mutation, Metabolic Immuno-Oncology, Microbiology, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, SARS-CoV-2 Viral Variants, TP53 - Germline mutations, Translational Research, Translational Science | Tagged : Immunotherapies, cancer genomics and therapy, cfDNA, ctDNA Liquid Biopsy, gut microbiome, human microbiome, molecular tumor board, multiomics platforms, spatial omics, theranostics | Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Omics Session Track 2 October 3 2025

October 3, 2025 by sjwilliamspa

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Omics Session Track 2 October 3 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

4:20-4:40

Jared K. Burks, PhD, Director, Flow Cytometry & Cell Imaging Core Facility, Department of Hematopoietic Biology & Malignancies,Division of Cancer Medicine; Associate Director of Shared Resources CCSG, Department of CCSG; Professor, Department of Hematopoietic Biology & Malignancies, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

 

• APOE was marker for defining a long term survivor and short term survivor for ovarian cancer patients; the markers were in the stroma
• there is spatial communication between tumor and underlying stroma
• it is imperative to understand how your multiomics equipment images a tumor area before it laser captures and send to the MS system; can lose a lot of tissue and information based on differences in resolution
• many of these multiomics systems are validated for the clinic in EU not US
• multiomics spatial analysis allows you to image protein, metabolite, mRNA expression in the 3 dimensional environment of the tumor (tumor cells and stroma)
• they are making a human tumor atlas
• they say a patient who had tumor went home during COVID and took vaccine but got ill with vaccine; but came back to check tumor and tumor had greatly regressed because prevaccine the tumor was immunologically cold and post COVID vaccine any left over tumor showed great infiltration of immune cells

4:40-4:55

Aruna Ayer, PhD, VP, Multiomics, Innovation and Scientific Affairs, BD Biosciences

• BD Bioscience multiomics platform is modular and can add more omics levels in the platorm
• for example someone wanted to look at T cells
• people have added CRISPR screens on the omics platform
• most people are using single cell spatial omics
• they have a FACS on their platform too so you can look at single cell spatial omics and sort different cellular populations
• very comparative to 10X Genomics platform
• their proteomics is another layer you can add on their platform however with proteomics you can high background notice with spatial proteomics or a limited panel of biomarkers
• Their OMICS Protein One panels are optimized for biology and tumor type.
• get high quality multiomics data and proteomics data but in a 3D spatial format
• developed Cellismo Data Visualization software tool

4:55-5:10

Harsha Gowda, PhD, Senior Principal Scientist, Director, Research & Lab Operations, Signios Bio

Signios Biosciences (Signios Bio) is the US-based arm of MedGenome, a global leader in genetic testing services, genomics research, and drug discovery solutions.

Signios Bio is a multiomics and bioinformatics company dedicated to revealing the intricate signals within biological data. We leverage the power of multiomics—integrating data from genomics, transcriptomics, proteomics, epigenomics, metabolomics, and microbiomics—to gain a comprehensive understanding of disease biology. Our AI-powered bioinformatics platform allows us to efficiently analyze these complex datasets, uncovering hidden patterns and accelerating the development of new therapies and diagnostics.

Through the integration of cutting-edge multiomics technologies, advanced bioinformatics, and the expertise of world-class scientists, we enable researchers and clinicians with comprehensive, end-to-end solutions to improve drug discovery and development and advance precision medicine.

As part of MedGenome, we have access to real-world evidence (RWE) from global research networks across the US, Europe, Asia, Africa, Middle East, and Latin America. This access enables us to work with our partners to uncover insights that can lead to new biomarkers and drug targets, ensuring that precision medicine is inclusive and effective for all.

https://www.signiosbiolcom 

• their platform can do high throughput analysis of patient tumors (like gallbladder cancer) analyzing mutational spectrum with high dimensionality
• they can integrate genomic and transcriptomics data to reveal multiple pathways affected in patient data
• have used their platform to investigate spatial omics in lung cancer

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Posted in Computational Biology/Systems and Bioinformatics, Metabolomics, Next Generation Sequencing (NGS), Personal Health Applications: Tech Innovations serves HealhCare, Personalized and Precision Medicine & Genomic Research, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, SARS-CoV-2, Tissue Microenvironment, Transcriptomics, Transformative Technologies in Healthcare, Translational Science, Uncategorized | Tagged BD Biosciences, bioengineering, multiomics, multiomics platforms, Signios Bio, spatial genomics, spatial proteomics, tumor microenvironment | 1 Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025

October 3, 2025 by sjwilliamspa

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

WIN SYMPOSIUM

1:50-4:05

SESSION 4

From Targets to Trials:
Translating Discovery into Impact

1:50-2:10

Beyond Checkpoint Inhibitors: Targeted Immunotherapeutic Approaches for the Management of Solid Tumors

Matthew Hadfield, DO, Assistant Professor of Medicine, Phase 1 Clinical Trials, Cutaneous Malignancies, The Warren Alpert Medical School of Brown University 

• we need to turn these immuno-cold tumors into immuno ‘hot’ tumors so immunotherapy will be effective and recognize them
• however each immunotherapies have their own toxicities
• immunocheck points inhibitors: 50% of patients get very rough adverse events and have to stop therapy and give immunosuppressives
• 60 yo female with urothelial carcinoma with chemo induced rash given pembrolizumab but got worse rash… had Steven Johnson Syndrome… fatal outcome from one cycle of PD-L1 inhibitor
• so now we are giving these immune checkpoints earlier before even surgery… the overall survival better but there are certain personalized toxicities
• up to 35% patients with cancer have chronic immuno related adverse events and dose limiting toxicities
• 50% have low grade multiple toxicities (and they treat these AEs with steroids)
• we have no biomarkers for these PD/PDL1 inhibitor adverse events

 

2:10-2:30

Implementing Molecular Profiling in Early Phase Clinical Trials: Precision from Bench to Bedside

Apostolia M. Tsimberidou, MD, PhD, FASCO, FAAAS, Tenured Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer

• power of biomarkers: BRCA2 null women with ovarian cancer success with olaparib even though at time was not approved except the biomarker known
• every week they discuss with internal tumor board and consult with Foundation Medicine; however a mutational panel is great but need to understand the underlying effect on tumor biology
• there are a handful of tumor agnostic targeted agents: based on biomarkers
• she thinks digital twins will be helpful in determining cohort selection for clinical trails
• she would like multiomics to be performed on every patient but how would this be done, especially in the ecosystem of the USA
• from attendee question to speaker panel (from Indai): they have been running tmolecular boards but problem is when new targets or fusion proteins become known without a priori knowledge of them and no combination know what to do?

 

:30-2:40

Q&A

Matthew Hadfield, DO, Assistant Professor of Medicine, Phase 1 Clinical Trials, Cutaneous Malignancies, The Warren Alpert Medical School of Brown University 

Apostolia M. Tsimberidou, MD, PhD, FASCO, FAAAS, Tenured Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer

2:40-3:20

Non- CME Session: Venture Philanthropy

Eric Heil, MBA, Managing Partner, Medical Excellence Capital

• started a venture fund and then a 501(c) to give small grants
• in venture philanthropy it is not traditional grant writing but more of a personal relationship; he says find other companies they have backed and ask them
• all about networking
• looked at 1400 deals but only invested in 13
• back years ago his company biotech got ten million after 2009 from TAP but now it seems smaller bridge money

John Lehr, President & CEO, Parkinson’s Foundation

• runs venture philanthropy which is more like a mix of venture fund and granting agency
• most run a for profit venture but mix model with 501c to fund small grants

Dr. Blaine Robinson, PhD, Vice President of the Therapy Acceleration Program (TAP), Blood Cancer United

• runs Blood Cancer United that offers grants for blood based research
• they run three pillars: venture biotech funding, clinical trial funding, and academic research but most they take equity in biotechs
• so venture philanthropy is more of equity investing and using those funds to fund younger companies like bridge between first round and series C
• Blood Cancer United looking for million and above investment “first in class’; was early with Kite and UPenn (where are they now… are they still with them?)

3:20-4:10

eNSCLC Testing

Kurt A. Schalper, MD, PhD, Associate Professor of Pathology and Medicine (Medical Oncology), Yale School of Medicine; Director Translational Immuno-Oncology Laboratory, Yale Cancer Center

• lung cancer has seemed to be ahead with respect to biomarkers and precision therapies
• at least with NCCN guidelines they are up to 14 therapeutic biomarkers not diagnostic biomarkers so very ahead on the clinical decision making on actionable mutations for lung cancer
• so most of the testing is genomic mutational spectrum for oncogenic drivers
• there are three protein based biomarkers: Met, PDL1,
• FISH is still used for some fusions
• NGS is more sensitive test but takes 2-4 weeks
• the number of  detected EGFR variants are increasing so it is affecting the drug specificity
• recently NRG1 fusions have been approved as a heregulin HER3 biomarker;
• 15% which were detected as negative for fusions the patients actually responded because fusions were hard to detect; many false positives
• 76% did not meet MET eligbility but only 13% were high enough for MET marker but was enough for FDA approval
• some drugs beneficial for mutated version and some good for over expressed like MET or HER2 but where the mutation or exon skipping is important for therapy choice
• we need better biobanking because we need more tissue; we loose more tissue during sectioning and not splitting blocks into two (one for diagnostic one for therapeutic)
• liquid biopsy will find some mutations but other ones not very sensitivity in liquid biopsy like MET mutations (mutations may be assay specific)
• some muts in bone marrow may just be in aging progenitor cells and sometimes in oncogene like BRAF but not cancer but dlonal homatopoesis (increased risk for myeloproliferative diseases but not solid tumors like melanoma)
• clonal homatopoesis actually common so watch out when just relying on liquid biopsy

 

 

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Posted in BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, BioTechnology - Venture Creation, Venture Capital, Cancer Informatics, Philanthropy to Academic Institution, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, Venture Capital | Tagged : Immunotherapies, adverse events, Biotech Investment and Venture Growth: The Franchising of Intellectual Property as a Business Model, Brown University, cancer adverse event, Clinical Trials, early ventures, Immune checkpoint inhibitors, MD Anderson Cancer center, PD-1/PDL1, PDL-1 biomarker, philanthropy | 1 Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference,Morning Session Track 1 October 3 2025

October 3, 2025 by sjwilliamspa

Real Time Conference Coverage: Advancing Precision Medicine Conference,Morning Session Track 1 October 3 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

 

Agenda Track 1: WIN Symposium

WIN SYMPOSIUM

Co-Chairs

Wafik S. El-Deiry, MD, PhD, FACP, Chair, WIN Consortium, Director, Legorreta Cancer Center Brown University, Director, Joint Program in Cancer Biology, Brown University and Brown University Health; Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University; Attending Physician, Hematology/Oncology, Brown University Health Mencoff Family University; Professor of Medical Science, Professor of Pathology and Laboratory Medicine, Brown University; Professor, American Cancer Society Research Professor

Razelle Kurzrock, MD, FACP, Chief Medical Officer, WIN Consortium; Professor of Medicine, Associate Director, Clinical Research, Linda T. and John A. Mellowes Chair of Precision Oncology, MCW Cancer Center and Linda T. & John A. Mellowes Center for Genomic Sciences and Precision Medicine

MULTI-OMICS

Chair

Arutha Kulasinghe, PhD, Associate Professor, Frazer Institute, University of Queensland; Founding Scientific Director, Queensland Spatial Biology Centre

8:40 – 9:00

Welcome and Introduction

Wafik S. El-Deiry, MD, PhD, FACP, Chair, WIN Consortium, Director, Legorreta Cancer Center Brown University, Director, Joint Program in Cancer Biology, Brown University and Brown University Health; Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University; Attending Physician, Hematology/Oncology, Brown University Health Mencoff Family University; Professor of Medical Science, Professor of Pathology and Laboratory Medicine, Brown University; Professor,American Cancer Society Research Professor

Dr. El-Diery welcomes all to this joint symposium with Advancing Precision Medicine and the Win Consortium, which he is currently the head of.  More in the WIN Consortium: (Worldwide Innovation Network Consortium in Precision Oncology).  The WIN Network  is involved in setting up internationalclinical tumor board collaboration

Source: https://winconsortium.org/ 

WIN was formed on the premise that we can accomplish more together than each organization can achieve working alone. We aim to improve cancer patients’ survival and quality of life. View WIN’s history and unique attributes:

• 01
  WIN History
• 02
  Diversity of Stakeholders – WIN Members
• 03
  Studies with a diverse, gender equality global population
• 04
  Sharing information to promote use of personalized, targeted cancer therapy: WIN Symposia

---

Clinical trials, projects and publications

WIN members collaboratively design and carry out global studies designed to achieve breakthroughs for patients worldwide. Our distinguished Scientific Advisory Board oversees WIN studies. Current trials include:

• 01
  Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors
• 02
  Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments
• 03
  SPRING – Landmark Lung Cancer Tri-Therapy Clinical Trial
• 04
  WINTHER: the WIN Consortium’s first global personalized medicine clinical trial, published in Nature Medicine

View a summary of the WIN Consortium here:

Click to access Brochure_WIN_v24.0_2025_08_13__.pdf

They guide WIN’s strategic, operational, and scientific direction.

OrganizationThe WIN Consortium is organized in the following groups who collectively work together to achieve WIN’s common goals

 

 

Nigel Russell, Founder and CEO, Advancing Precision Medicine

Christopher P. Molineaux, President & Chief Executive Officer, Life Science Pennsylvania

Life Sciences Pennsylvania (LSPA) is the statewide trade association for the commonwealth’s life sciences industry. Founded in 1989, LSPA works to ensure Pennsylvania has a business and public policy climate that makes the commonwealth the most attractive location to open and operate a life sciences company. Our membership is comprised of organizations statewide, representing the entire ecosystem of the life sciences: research institutions, biotechnology, medical device, diagnostic, pharmaceutical, and investment entities, along with service providers who support the industry. Together, we unify Pennsylvania’s innovators to make the Commonwealth a global life sciences leader.

As president & CEO of Life Sciences Pennsylvania, Christopher Molineaux serves as the chief advocate and spokesman for the life sciences industry that calls Pennsylvania home. Molineaux oversees the strategic direction for the association, assuring Life Sciences Pennsylvania continues to be the catalyst that makes Pennsylvania the top location for life sciences companies.

Molineaux brings to Life Sciences Pennsylvania more than 25 years of experience in the bio-pharmaceutical and health care industries, with front-line experience in developing and executing strategies to navigate a shifting economic and political environment.

9:00-9:40

Keynote Lecture – WIN Consortium

Targeting the Achilles’ Heel of Cancer: Synthetic Lethality and Hypoxia in Precision Oncology

William G. Kaelin, Jr, MD,  2019 Nobel Laureate, Sidney Farber Professor, Harvard Medical School and Dana-Farber Cancer Institute

William Kaelin was born in New York City. He studied chemistry and mathematics at Duke University in Durham, North Carolina, and received his doctor of medicine degree there in 1982. He then did his residency at Johns Hopkins University in Baltimore, Maryland. In 2002 he became a professor at Harvard Medical School in Cambridge, Massachusetts.

Work

 

Animals need oxygen for the conversion of food into useful energy. The importance of oxygen has been understood for centuries, but how cells adapt to changes in levels of oxygen has long been unknown. William Kaelin, Peter Ratcliffe, and Gregg Semenza discovered how cells can sense and adapt to changing oxygen availability. During the 1990s they identified a molecular machinery that regulates the activity of genes in response to varying levels of oxygen. The discoveries may lead to new treatments of anemia, cancer and many other diseases.

TRACK 1  204BC

 

WIN SYMPOSIUM

MULTI-OMICS

9:40 – 10:40

SESSION 1

From Base Pairs To Better Care:

AI and Omics in Precision Oncology

9:40-10:00

Multi-Omic Profiling and Clinical Decision Support in Precision Oncology

David Spetzler, PhD, MBA, MS,  President, Caris Life Sciences

10:00-10:20

Integrating Omics and AI for Next-Gen Precision Oncology

Keith T. Flaherty, MD, FAACR, Director of Clinical Research, Massachusetts General Cancer Center; Professor of Medicine, Harvard Medical School;
President-Elect: 2025-2026, American Association for Cancer Research (AACR) 

10:20-10:40

Real-World Data and AI in Precision Oncology: Making Data Work for Patients – Q&A

MODERATOR: Jeff Elton, PhD, Vice Chairman, Founding CEO
ConcertAI

PANELISTS: David Spetzler, PhD, MBA, MS, President, Caris Life Sciences

Keith T. Flaherty, MD, FAACR, Director of Clinical Research, Massachusetts General Cancer Center; Professor of Medicine, Harvard Medical School;
President-Elect: 2025-2026, American Association for Cancer Research (AACR) 

0:40 – 11:10

Break and Exhibits

TRACK 1  204BC

TRACK 2  204A

WIN SYMPOSIUM

MULTI-OMICS

11:10 – 1:10

SESSION 2

The Evolution of Precision Oncology:

Integrating MRD, AI, and Beyond

11:10-12:00

Precision Cancer Consortium

Gabriele Allegri, MBA, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

Shruti Mathur, MS, Pharma Diagnostic Strategy Leader, Global Product Strategy (GPS), Genentech

Daryl Pritchard, PhD, Interim President, Personalized Medicine Coalition

Keith T. Flaherty, MD, FAACR, Director of Clinical Research, Massachusetts General Cancer Center; Professor of Medicine, Harvard Medical School;
President-Elect: 2025-2026, American Association for Cancer Research (AACR) 

SESSION 3

The Shifting Landscape:

Tumor Plasticity and Resistance

12:00-12:20

Mathematical and Evolutionary Modeling in Precision Radiation Oncology

Jacob Scott, MD, DPhil, Professor and Staff Physician-Scientist, CWRU School of Medicine and Cleveland Clinic

12:20-12:40

Plasticity and Persistence: The Role of EMT in Cancer Progression and Therapy Resistance

Sendurai A. Mani, PhD, Professor of Pathology and Laboratory Medicine, Brown University; Associate Director of Translational Oncology, Brown University Legorreta Cancer Center

12:40-1:00

Targeting Molecularly Defined Subsets: Challenges in Translational Oncology

Benedito A. Carneiro, MD, MS, Director, Clinical Research
Director, Cancer Drug Development; Associate Director, Division of Hematology/Oncology
Legorreta Cancer Center, Brown University Health

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Posted in Biological Networks, Cancer Genomics, Clinical Genomics, Evidence-based decision-making, Nobel Prize Winners, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Single Cell Genomics, Transcriptomics, Translational Research, Translational Science | Tagged Advancing Precision Medicine, biomedical collaboration, gene expression profiling, genomics, HIF-1a, international consortium, liquid biopsy, mutational specrum, nobel leureates, oncogenes, Personalized and Precision Medicine & Genomic Research, Transcriptomics, Warburg Effect | Leave a Comment »

« Newer Posts - Older Posts »

• Follow Blog via Email

  Enter your email address to follow this blog and receive notifications of new posts by email.

  Email Address

  Follow

  Join 2,041 other subscribers

• Recent Posts

  • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
  • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
  • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
  • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
  • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
  • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
  • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
  • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
  • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI-in-Health, Life Sciences & BioPharma June 15, 2026
  • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026

• Archives

  Archives Select Month August 2026  (2) July 2026  (6) June 2026  (4) May 2026  (1) January 2026  (10) December 2025  (8) November 2025  (8) October 2025  (12) September 2025  (2) July 2025  (4) June 2025  (8) May 2025  (4) April 2025  (2) March 2025  (1) February 2025  (2) January 2025  (3) December 2024  (1) November 2024  (5) October 2024  (7) September 2024  (7) August 2024  (1) June 2024  (1) May 2024  (2) April 2024  (2) January 2024  (1) November 2023  (1) October 2023  (3) September 2023  (3) August 2023  (2) July 2023  (2) June 2023  (7) May 2023  (4) April 2023  (2) March 2023  (5) February 2023  (2) January 2023  (3) December 2022  (2) October 2022  (6) September 2022  (2) August 2022  (1) July 2022  (3) June 2022  (3) May 2022  (8) April 2022  (10) March 2022  (7) February 2022  (7) January 2022  (3) December 2021  (3) November 2021  (4) October 2021  (11) September 2021  (5) August 2021  (8) July 2021  (21) June 2021  (8) May 2021  (10) April 2021  (8) March 2021  (15) February 2021  (17) January 2021  (20) December 2020  (10) November 2020  (12) October 2020  (26) September 2020  (17) August 2020  (22) July 2020  (27) June 2020  (33) May 2020  (26) April 2020  (42) March 2020  (22) February 2020  (11) January 2020  (7) December 2019  (20) November 2019  (13) October 2019  (11) September 2019  (3) August 2019  (8) July 2019  (25) June 2019  (47) May 2019  (40) April 2019  (27) March 2019  (29) February 2019  (17) January 2019  (50) December 2018  (14) November 2018  (17) October 2018  (18) September 2018  (17) August 2018  (8) July 2018  (20) June 2018  (22) May 2018  (17) April 2018  (12) March 2018  (20) February 2018  (26) January 2018  (16) December 2017  (6) November 2017  (20) October 2017  (13) September 2017  (16) August 2017  (16) July 2017  (19) June 2017  (20) May 2017  (32) April 2017  (21) March 2017  (10) February 2017  (24) January 2017  (21) December 2016  (43) November 2016  (8) October 2016  (40) September 2016  (67) August 2016  (59) July 2016  (75) June 2016  (37) May 2016  (95) April 2016  (152) March 2016  (175) February 2016  (196) January 2016  (139) December 2015  (90) November 2015  (287) October 2015  (237) September 2015  (115) August 2015  (96) July 2015  (63) June 2015  (44) May 2015  (53) April 2015  (76) March 2015  (95) February 2015  (83) January 2015  (75) December 2014  (75) November 2014  (88) October 2014  (135) September 2014  (117) August 2014  (88) July 2014  (88) June 2014  (109) May 2014  (60) April 2014  (85) March 2014  (58) February 2014  (72) January 2014  (107) December 2013  (104) November 2013  (136) October 2013  (62) September 2013  (32) August 2013  (46) July 2013  (74) June 2013  (110) May 2013  (112) April 2013  (86) March 2013  (92) February 2013  (63) January 2013  (63) December 2012  (46) November 2012  (71) October 2012  (84) September 2012  (82) August 2012  (122) July 2012  (59) June 2012  (34) May 2012  (46) April 2012  (2)

• Categories

  Categories Select Category 3D Printing for Medical Application  (239)    3D Plotting Scaffolds  (44)    BioInks  (34)       Biopolymer Blend Open Porous  (18)       Dental Applications  (10)    BioPrinting in Regenerative Medicine  (77)       Cell Level  (16)       MicroEngineering Cell-Tissue & Systems  (31)       Tissue Engineering  (37)    Cardiovascular and Vascular Systems  (30)       Artificial Vascular Structures  (9)       Cardiovascular Tissue  (8)    Drug Development using MultiOrgan Chip  (11)    Drug Development/Formulation using 3D Printing  (10)    MEMS  (16)       Bio-MEMS  (12)    Organ-on-a-Chip  (11)    Programmable Sensors (Carbon Nano Tubes)  (5) 3rd Party IP: Drug DIscovery  (1) 4D Printing and Meta Materials  (10) Academic Publishing  (223)    Key Opinion Leaders in eScientific Publishing – Interviews with  (8) Advanced Drug Manufacturing Technology  (96)    Antimalarial Preparation  (8)    Autologous Cell Therapy  (14)    Automated Cell Processing  (13) Allergy and Infectious Diseases  (12) Alzheimer’s Disease  (163)    Etiology  (77)    Medical Device Therapies for Altzheimer’s Disease  (15)    Pharmacotherapy and Cell Activity  (51) Anticancer Resistance  (31) Art Exhibits on the Human Condition  (1) Art Inspires Science  (4) Article Type  (2)    Authored  (1)    Curated  (2)    Scientific report  (1) Artificial Heart  (2) Artificial Intelligence – General  (239)    An executive’s guide to AI  (11)    Artificial Intelligence – Breakthroughs in Theories and Technologies  (119)    Artificial Intelligence Applications in Health Care  (130)       Artificial Intelligence in CANCER  (42)       Artificial Intelligence in Health Care – Tools & Innovations  (77)    Artificial Intelligence in Medicine – Application for Diagnosis  (72)       Artificial intelligence applications for cardiology  (33)          AI-assisted Cardiac MRI  (10)       Artificial Intelligence in Psychiatry  (7)       Deep Learning in Pathology  (19)    Artificial Intelligence in Medicine – Applications in Therapeutics  (71)    ChatGPT, GPT-4  (7)       ChatGPT at LPBI Group  (3)       ChatGPT in Academic Education  (3)    Machine Learning  (73)       Deep Learning  (26)       Natural Language Processing (NLP)  (45)    Machine learning in predicting type 2 diabetes  (6) Auditory and vision  (13) Autism Spectrum Disorders  (10) Autoimmune Inflammatory DIseases  (24)    Crohn’s disease  (5)    Tolerance-inducing Autoimmune Disease Therapeutics  (6)    Ulcerative Colitis  (3) Autophagosome  (4) Bacterial Resistance  (25) Behavior  (26) Behavioral Genetics  (21) Big Data  (88)    Intelligent Information Systems  (51) Bio Instrumentation in Experimental Life Sciences Research  (368)    Analytical Instruments Industry  (5)    Microfuidics  (8) Bio-Ethics  (16) BioBanking  (36) Biodegradable Drug-eluting Material  (8) Bioengineering & reverse engineering design  (43) BioIT: BioInformatics  (147) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics  (135)    Advanced Computing Platform  (32)       Blockchain Transactions System  (6)          Platform for Content Monetization embedded Content Promotion  (1)    Pancreatic adenocarcinoma classifier  (4)    Simulation Modeling in NGS  (5) Biological Engineering  (43) Biological Networks  (193) Biological Networks, Gene Regulation and Evolution  (479)    Virology  (10) Biomarkers & Medical Diagnostics  (571)    VOC – Volatile Organic Compounds as BioMarkers  (2) Biomedical Measurement Science  (173) BioSimilars  (112) BioTechnology – Venture Creation  (133)    Foundations for supporting Science and Education  (14)    Philanthropy to Academic Institution  (3) BioTechnology – Venture Creation, Venture Capital  (110)    Seeking Talent  (3) BiVAD  (1) Blindness  (6) Bone Disease and Musculoskeletal Disease  (82) Brain Basis of Emotion  (5) Business Career Consideration  (1) Ca2+ triggered activation  (61) Calcium  (21) Calcium Signaling  (71) Calmodulin Kinase and Contraction  (36) Cancer – General  (186) Cancer and Current Therapeutics  (412)    interventional oncology  (49)       Breast Cancer – impalpable breast lesions  (20)       Prostate Cancer: Monitoring vs Treatment  (9) CANCER BIOLOGY & Innovations in Cancer Therapy  (1,127)    Anaerobic Glycolysis  (51)    Cachexia  (18)    Cancer Genomics  (85)       Circulating Tumor Cells (CTC)  (27)          Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood  (17)             mRNA  (6)          MagSifter chip  (1)       KRAS Mutation  (9)       Li-fraumeni syndrome.  (4)       TP53 – Germline mutations  (9)    cancer metabolism  (28)    Funding Opportunities for Cancer Research  (13)    Genomic Expression  (150)    Glioblastoma  (7)    Hexokinase  (14)    Loss of function gene  (18)    Metabolic Immuno-Oncology  (21)    Metastasis Process  (15)    Methylation  (33)    Microbiome and Responses to Cancer Therapy  (10)    Monoclonal Immunotherapy  (29)    mtDNA  (13)    Oxidative phosphorylation  (56)    Pancreatic cancer  (10)    Pyruvate Kinase  (27)    The NCI Formulary  (1)    tumor microenvironment  (16)    Warburg effect  (50) Cancer Informatics  (104) Cancer Prevention: Research & Programs  (132) Cancer Screening  (108) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy  (30)    Engineering Enhanced Cancer Vaccines  (3) cancer-general  (7) Cardiac and Cardiovascular Surgical Procedures  (328)    Aortic Valve: TAVR, TAVI vs Open Heart Surgery  (91)       Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR  (2)       TAVI vs Open Heart Surgery  (6)       Transcatheter Aortic Valve Replacement via the Transcarotid Access  (3)       Transcaval TAVR Procedure  (3)       Valve-in-Valve Procedure  (5)    Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias  (18)    BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy  (1)    CABG  (47)    Cancer Surgery of the Heart  (10)    Cardiovascular Fluid Management: algorithms  (1)    Heart Transplant  (16)    Heart-Lung Transplant  (11)    Implantation  (3)    Left Main Coronary Artery Disease (LMCAD)  (3)    Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart  (22)    Mitral Valve: Repair and Replacement  (64)       TMVR – Transcatheter Mitral Valve Repair  (5)    PCI  (108)       Bioresorbable Vascular Scaffold (BVS)  (4)       Invasive FFR for PCI  (2)       Multivessel PCI FFR Guidance  (1)       Robotic-assisted percutaneous coronary intervention  (2)       Stent Retriever in endovascular thrombectomy  (3)    Peripheral Arterial Disease & Peripheral Vascular Surgery  (65)       Abdominal Aorta  (20)       Carotid Artery  (15)       Limb ischemia  (4)       Thoracic Aorta  (16)    Pulmonary Valve Replacement and Repair  (3)    Renal Denervation  (20)    Replacement  (1)    Robotically assisted Cardiothoracic Surgery  (2)    Tricuspid Valve Repair  (7)    Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis  (2) Cardiovascular Pharmacogenomics  (171) Cargo  (3) Cell Biology  (323) Cell Biology, Signaling & Cell Circuits  (672)    Apoptosis  (17)    Autophagy-Modulating Proteins  (6)    “Antibody–enzyme conjugates”  (6)    Cell Processing System in Cell Therapy Process Development  (27)    Endoplasmic reticulum  (3)    Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)  (3)    Ubiquitin  (11) Cerebrovascular and Neurodegenerative Diseases  (123)    Stroke  (9) Chemical Biology and its relations to Metabolic Disease  (464)    #BIGAxisSummit  (1)    Gut Microbiome and Obesity  (8) Chemical Genetics  (350) Child and Adolescent Psychiatry  (13) Childhood cancer  (17) Childhood malnutrition  (3) children  (4) Circulating Progenitor Cells  (27)    Bone marrow derived cells  (17)    Endothelial cells  (7)    Umbilical cord cells  (6) Clinical & Translational  (239) Clinical Diagnostics  (220)    Mass automation of plasma proteins  (13) Clinical Genomics  (144) Coagulation Therapy and Internal Bleeding  (83) Cognition  (47) Commercialization  (20) Components and IRB related issues  (4) Computational Biology/Systems and Bioinformatics  (470)    Computational Histopathology  (3)    Meta-analysis of transcriptome data  (10) Conference Coverage with Social Media  (494)    MassBio  (3) coronavirus  (18) COVID-19  (20) CRISPR/Cas9 & Gene Editing  (192)    CRISPR alternative for editing genes without cutting  (14)       CAST – Alternative to CRISPR/Cas9  (3)       Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration  (4)    CRISPR applied to Human Germ Line  (13)       Gene Editing Impact on Longevity  (6) CT  (20) Cytokines  (21) Cytoskeleton  (85) Developmental biology  (107) Diabetes Mellitus  (146)    Artificial Pancreas for Type 2 Diabetes  (4)    Artificial Pancreas for Type1 Diabetes  (8)    Gestational diabetes  (5) Diagnostic Immunology  (61) Diagnostics and Lab Tests  (128)    Liquid Biopsy: Circulating Tumor Cells in Urine and Blood  (9) Digital HealthCare – biotech & internet joint ventures  (47) Disease Biology  (334) Disease Biology, Small Molecules in Development of Therapeutic Drugs  (488) DNA repair  (73)    Apoptosis  (13)    Autophagy  (13)    Cell death pathways  (19)    Proteolysis  (8)    Proteosome  (8) Drug Delivery Platform Technology  (159)    Drug Carrier Design  (21)       Medication Remote Compliance Monitoring  (3)    Exosomes: Natural Carriers for siRNA Delivery  (9) Drug Toxicity  (74) Ecosystems & Industrial Concentration in the Medical Device Sector  (172)    Cardiac & Vascular Repair Tools Subsegment  (128)    Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment  (14)    Massachusetts Niche Suppliers and National Leaders  (20) Electronic Health Record  (10) Embryology  (24) Empathy  (6) Endocrine Diseases  (60) Enzyme Induction  (46)    ion-transporting enzyme  (2)    K + -ATPase.  (1)    Na +  (2) Epigenetics and Environmental Factors  (35) Ethics and Leadership  (10) Executive Compensation – Big Pharma  (3) Fat soluble vitamins  (4) FDA  (72) FDA Regulatory Affairs  (359)    FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155  (52)    ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics  (30) Fetal Ultrasound  (2) Fiction and medicine  (5) Frontiers in Cardiology and Cardiovascular Disorders  (929)    Acute Myocardial Infarction  (63)       Cardiogenic Shock  (5)    Anemia in CVD Patients  (6)    Cardio-Oncology  (4)    Cardiomyopathy  (57)    Cardiovascular Research  (187)       Myocardial metabolism, Myocardial ischemia, myocardial perfusion, Myocardial adenine nucleotide metabolism  (64)       Pre-Clinical Animal Model Development  (23)    Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH)  (20)    Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission  (1)    Electrophysiology  (111)       Ablation Procedure vs Drug Therapy  (2)       Arrhythmia Detection with Machine Learning Algorithms  (7)       Cardiotoxic Risks of Immune Checkpoint Inhibitors  (1)       Genomic Analysis of EKG Electrophysiology Genomics  (3)       implantable cardioverter defibrillator (ICD) and External Defibrillation  (1)       implantable pacemaker  (2)       Rare heart rhythm disorders and Long QT syndrome (LQTS)  (7)    Epigenetics and Cardiovascular Risks  (57)    Heart Failure (HF)  (51)       Acute coronary syndrome  (7)       congestive heart failure  (19)       Hypertensive Disorders of Pregnancy  (1)    Medical Devices R&D and Inventions  (212)       Assist Devices: LV  (3)       RV  (1)       Stents & Tools  (90)       Valves & Tools  (67)    Origins of Cardiovascular Disease  (422)       Atherogenic Processes & Pathology  (180)       Congenital Heart Disease  (34)          Genetic Mutations in Congenital Heart Disease  (4)       inflammation independent of lipid levels  (13)       Systemic Inflammatory Diseases as CVD Risk  (12)    Pharmacotherapy of Cardiovascular Disease  (356)       HTN  (176)       HTN in Youth  (8)       Resident-cell-based  (43)       Subarachnoid Hemorrhage (SAH)  (1)       Transthyretin amyloid cardiomyopathy (ATTR-CM)  (1)    Spontaneous Coronary Artery Dissection (SCAD)  (6)    Stroke  (15)       endovascular thrombectomy  (6)    Vascular Diseases  (21)       mesenteric ischemia  (3) Future Pandemics Inform-graphics  (1) Gastroenterology  (38) Gene Regulation  (233) Gene Regulation and Evolution  (137) Genetics & Innovations in Treatment  (176) Genetics & Pharmaceutical  (204) Genome Biology  (967)    Exosomes  (25)    Gene Therapy & Gene Editing Development  (42)    mRNA Therapeutics  (20)    Mutagenesis  (27)    Single Cell Genomics  (25)    Single-cell sequencing  (20)    Variation in human protein-coding regions  (35) Genomic Endocrinology  (42) Genomic Testing: Methodology for Diagnosis  (416) Genomics Pharmacy  (40) Global Market of Medical Devices Technology  (3) Global Medical Publishers by Country  (3) Global Partnering & Biotech Investment  (48) GLP  (4) Glycobiology: Biopharmaceutical Production  (16) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics  (28) Health Care System by Country  (58)    AI Models in Healthcare  (12)    Centers for Medicare & Medicaid Services  (8)    Health in Israel  (2)    India  (1)    United States  (27)       Hospital-based Medical Innovations  (10)       Medical Recertification and Maintenance of Certification (MOC)  (1) Health Economics and Outcomes Research  (384)    Women Health  (18)       Heart and Brain Disease in Women  (3) Health Law & Patient Safety  (165)    and Bioethics  (14)    Biotechnology  (12)    Health Law Policy  (13) HealthCare IT  (139) Healthcare Reform  (118)    Accountable Care Organizations  (26)    Affordable Care Act  (29)       Repair  (1)       Repeal ACA  (1)       Replace  (1)    Federal Budget Appropriations  (27)    Healthcare costs and reimbursement  (59)    Indigent Nutrition  (14)    Medicare and Medicaid  (20)    Prescription Drugs Costs  (21)    Skilled Nursing Facilities  (6)    Technology Capital Expenses  (15)    Uninsured and Underinsured  (20) Hematology  (100)    Acute lymphocytic leukemia  (18)    Acute myelocytic leukemia  (21)    Hematopoiesis  (48)    Lymphoma  (21) History and physical exam  (6) Human aging  (27) Human Immune System in Health and in Disease  (246) Human Sensation and Cellular Transduction: Physiology and Therapeutics  (21) Image Processing/Computing  (41) Imaging-based Cancer Patient Management  (116) Immuno-Oncology & Genomics  (133)    mRNA platform in Drug DIscovery  (6) Immunodiagnostics  (141)    Cancer-Immune Interactions  (31)    CNS-Immune Interface  (5)    Neuronal Circuits  (4) Immunology  (123)    Adaptive Immune Response to Biomaterials and Tissue Repair  (13)    Antibody Responses Predict Antigen Exposure  (17)    Cytokine Receptor Structure  (8)    Human Antibody Response  (18)    Human Circulating Antibody Repertoire  (11)    Human Naive B Cell Repertoire  (8)    MHC Repertoires for Antigen Prediction  (8)    Protection Against Autoimmune Disease  (11)    Synthetic Immunology: Hacking Immune Cells  (15) Immunotherapy  (136)    CAR-T  (16)    combination immunotherapies.  (15)    Efficacy of Anti-Tumor T Cells  (15)    Engineering Better T Cells  (10)    Immune Engineering  (18)    Immune Modulatory  (16)    Integrin-targeted Combination Immunotherapy  (6)    Modulating Macrophages in Cancer Immunotherapy  (17)    NK Cell-Based Cancer Immunotherapy  (20)    Synergistic Innate and Adaptive Immunotherapy  (14) Income Disparity  (2) Infectious Disease & New Antibiotic Targets  (162)    Antibiotic resistance  (7)    Viral diseases  (37)       Myocarditis  (1) Infectious Disease Immunodiagnostics  (58)    Virology – Vector-borne DIsease  (17) Inflammasome  (29)    Anti-tumor necrosis factor drugs (TNF inhibitors)  (3) Innovation in Immunology Diagnostics  (111)    Universal Immune Cell Therapies (uICT)  (11) Innovations  (186)    R&D Expenditure  (8) Innovations in Neurophysiology & Neuropsychology  (145)    Age and Life Expectancy  (3)    autism spectrum disorder  (1)    Circadian Rhythm and Sleep  (6)    hNPCs  (1)    Nervous System Function  (2)    Relapsing Multiple Sclerosis  (1) Intellectual Property  (85)    Disputes and Settlements  (9)    IP Valuation Models – Pricing Intangible Assets  (7)    Patent Law in Biotech  (12) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough  (121) International Global Work in Pharmaceutical  (191) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE)  (12) Interviews with Scientific Leaders  (319)    Albany Medical Center Prize in Medicine and Biomedical Research  (3)    Annual Breakthrough Prize  (4)    Annual Lewis S. Rosenstiel Award  (2)    Awards in Cardiology and Cardiovascular Medicine  (6)    CEOs of Biotech Companies  (3)    Gerald D Aurbach Award for Outstanding Translational Research  (2)    Interviews with Key Opinion Leaders (KOLs)  (11)    James Prize in Science and Technology Integration  (2)    Jessie Stevenson Kovalenko Medal – Medical Sciences  (2)    Lemelson-MIT Prize  (2)    Life Sciences Breakthrough Prize  (6)    Mosteller Statistician of the Year Award  (2)    Mourning the Loss of a Scientific Leader  (6)    National Academy of Sciences AWARDS  (4)    Nobel Prize Winners  (30)    Noble Prize (Not Nobel Prize)  (2)    Paul Marks Prize for Cancer Research  (2)    Russ Prize recognizes bioengineering achievements worldwide  (2)    The Dan David Prize  (6)    Warren Alpert Foundation Prize Recipients  (4)    Wolf Prize  (2)    Wolf Prize in Medicine  (2)    women in science  (5) Investment in Technological Breakthrough  (60) Ionic Transporters Na+  (25) IP Development by LPBI Group Team  (14) IP Development by LPBI Group Team & Other Organizations  (8) ISO 14155  (3) Joint Venture – SBH & M3DP: SOP and Arrangements  (1) Justice & Law  (1) K  (15) Lab-on-a-chip  (2) Landscape  (1) Lasers and photonics  (18)    Midrange IR spectroscopy  (1) Law and Medicine Conflicts  (15) Leadership, Power, Social Interlocking Connections  (13) Lipid metabolism  (109)    Fatty acids  (38)    Lipids  (38)    PCSK9 Inhibitor Therapy  (19) Lipidomics  (11) Liposome  (4) Liver & Digestive Diseases Research  (122) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management  (143)    Award Nominations  (5)    BioMed e-Books e-Series by LPBI Group  (9)    Feedback from Investors: LPBI Portfolio of Five Businesses  (2)    LPBI Group Founder – Aviva Lev-Ari  (27)    PhD  (1)    RN  (1) LPBI Management  (23) Massachusetts Academy of Sciences (MAS)    (2) Materials Science & Engineering  (37)    Organic BioElectronics  (2) Math  (13)    Great Discoveries  (7) Mechanical Assist Devices: LVAD  (4) Medical and Population Genetics  (193) Medical Devices R&D Investment  (242)    21st Century Cures Act  (2)    CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP  (14)    Rhythm management device hardware: dual-chamber pacemakers  (1)       Systolic HTN  (1) Medical Imaging Technology  (59) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound  (164)    Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI)  (3)    Echocardiography  (3)    MRI  (18)    Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT  (6)    Ultra Sound  (10) Melatonin & Circadian Regulation  (9) memory loss  (1) Metabolism  (239)    Biochemical pathways  (144)       Enzymes and isoenzymes  (73)          Dehydrogenase  (16)          Kinase  (28)          Phosphatase  (9)          Phosphorylase  (22)          tyrosine decarboxylases  (3)    Inosine nucleotides  (9)    Leloir pathway  (6)    microbiome  (7)    Pentose monophosphate shunt  (14)    Pyridine nucleotides  (28)       Pyridine nucleotide transhydrogenase  (7) Metabolomics  (321) Methods  (37) Mg++  (10) Microbiologial genetics  (36) Microbiology  (68)    Virology  (14) Micronutrients  (16) Microvesicle  (7) Microwave Ablation and Irreversible Electroporation (IRE)  (1) Mobile Healthcare  (5) Molecular Genetics & Pharmaceutical  (377)    Organoids  (3) Monoclonal antibody therapy  (14) Mutant Gene Expression  (42) Myocardial adenine nucleotide metabolism  (6) Myocardial Ischemia  (26) Myocardial Metabolism  (36) Na-K transport  (40) Na-K-ATPase  (27) Nanotechnology for Drug Delivery  (99) Nephrology  (46) Nephrology & Regenerative medicine  (9) Neurodegenerative Diseases  (89)    hNPCs  (3)    MS  (5) Neurohumoral Transmission  (68)    Ca2+ triggered activation  (21)    Calmodulin  (13)    Parkinson’s disease dyskinesia levodopa  (3)    PKC  (13)    Synaptic vesicle  (20) Neurological Diseases  (121) Neuroscience  (126) Next Generation Sequencing (NGS)  (27)    Nanopore sequencing  (1) NIH Common Fund  (1) Nitric Oxide in Health and Disease  (136) Nuclear Medicine  (11) Nutrigenomics  (68) Nutrition  (195)    Nutritional Supplements: Atherogenesis, lipid metabolism  (50) Nutrition and Phytochemistry  (62)    Minerals in Medicine  (4)    Plant extract  (22) Nutrition Disorders  (31) Nutritional Supplements: Atherogenesis  (31) Obesity  (19) Oligonucleotide Therapeutics & Delivery  (7) Oncolytic virus & OncoViro-Therapy  (23)    Synthetic Virology  (1) Organ-on-a-Chip & 3D Printing in Life Sciences  (7) Pain: Etiology, Genetics & Innovations in Treatment  (24) Parasitology  (5)    Malaria  (4)    Tropical diseases  (1) Patents  (35) Patient Experience  (66)    Art therapy  (1)    Hospital reputation  (7)    Humor  (1)    Music therapy  (2)    Pain Alleviation  (7)    Patient Outlook  (28)    Reputation of Interventionist  (4)    Support Staff  (13)    Supportive therapies  (6)       laughfter  (1)    Surgical Procedure  (9) Patient Experience: Personal Memories of Invasive Medical Intervantion  (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures  (18) Perioperative Statins at Noncardiac Surgery  (2) Personal Health Applications: Tech Innovations serves HealhCare  (43) Personalized and Precision Medicine & Genomic Research  (739)    Longevity  (3)    New Drug Approval  (6)    Patient-centered Medicine  (39)       cell-based therapy  (9)       stem cell biology and patient-specific  (7)    Personalized Medicine Coalition  (10)    Precision Cancer Medicine  (33) Phagophore  (2) Pharmaceutical Analytics  (261)    Pharmacologic toxicities  (62) Pharmaceutical Discovery  (111)    Rapid automation of plasma protein pools  (18) Pharmaceutical Drug Discovery  (206)    Drug Development Process  (61)       Drug Discovery Chemistry  (33)    drug repurposing  (11) Pharmaceutical Industry Competitive Intelligence  (346)    Pharmacovigilance  (7)    Value-based Drug Pricing  (8) Pharmaceutical R&D Informatics  (45) Pharmaceutical R&D Investment  (301) Pharmacodynamics and Pharmacokinetics  (24) Pharmacogenomics  (161) Photography Collection  (1) Physics  (12) Placenta  (7) Population genetics  (27) Population Health Management  (205)    Evolution of Biology Through Culture  (14)    U.S. Employment-to-Population Ratio  (8) Population Health Management, Genetics & Pharmaceutical  (643)    COVID-19  (157)       Biomarkers: Inflammation  (37)       Cancer Researchers Fighting COVID-19  (14)       COVID-19 effects on Human Heart  (15)       COVID-19: Pandemic Surgery Guidance  (19)       Economic Impact of Coronavirus Pandemic  (41)       number of asymptomatic infections  (27)       Treatment Protocols for COVID-19  (62)    SARS-CoV-2  (141)       Coronavirus Gene Expression  (66)          SARS-CoV-2 circulating variants   (14)          SARS-CoV-2 Viral Variants  (19)       Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis  (2)       Immune-Mediation (independent immunopathology: lung and reticuloendothelial system)  (30)       Mechanisms of infection by SARS-CoV-2  (21)       SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus  (35)          SARS-COV2 Hijacking the Complement and Coagulation Systems  (19)       Seasonality & Environmental Factors in Resurgence  (26)       Serology tests for coronavirus antibodies  (44)       T-cell response to SARS-CoV-2 infection  (14)       Vaccinology  (51)          Mechanism of Thrombosis with AZ & J&J COVID-19 Vaccines  (5)       Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins  (8)    Virus Infective Acute Respiratory Syndrome: SARS-CoV  (92) Population Health Management, Nutrition and Phytochemistry  (162) Preimplantation Genetic Diagnosis and Reproductive Genomics  (13) Protein-energy malnutrition  (12) Proteomics  (367)    Amino acids  (54)    Proteins  (138) Pulmonary diseases  (16)    Lung and pulmonology  (15) Pulmonary pathology  (8) Radio Frequency (RF)-based Surgical Solutions  (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session  (50) Regenerative Biology and Medicine  (92) Regulated Clinical Trials: Design, Methods, Components and IRB related issues  (265) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics  (113) Reproductive Biology & Bio Instrumentation  (78) RNA Biology  (81)    RNA interference (RNAi) therapeutic  (4) RNA Biology, Cancer and Therapeutics  (64) RVAD  (1) SBIR, SBA, NIH, NSF  (3) Schizophrenia  (16) Scientific & Biotech Conferences: Press Coverage  (182) Scientific Publishing  (609)    Curation  (585)       Curation methodology  (40)       De novo synthesis  (16)       Dialectic  (17)       Discovery process  (72)       Evolutionary cognition  (52)       Experimental validation  (91)       Explanatory  (91)       Historical relevance  (71)       Technology Advance Assessment of  (69)       Theoretic convergence  (27)    Open Access Journals  (37) Scientist: Career considerations  (198)    Big Data & Analytics  (17)    Data Science  (13)    Women in Life Sciences  (12) Scoop.it  (19) Sensors & Analytics  (18) Sepsis  (2) Severe Autism  (3) Signaling  (102)    Phosphorylation  (43)    S-nitrosylation  (13)    Ubiquitinylation  (34) Signaling & Cell Circuits  (130) single cell sequencing  (3) Small Molecules in Development of Therapeutic Drugs  (71) Social Development  (15) Specialized 3D BioPrinters (Cornea  (1) Statistical Methods for Research Evaluation  (137) Stem Cells for Regenerative Medicine  (177)    Cardiac muscle regeneration  (19)    Competition in regenerative stem cell science  (18)    Human neural progenitor cells  (8)    Skeletal muscle regeneration  (9) STORM  (2) Stress Disorders  (19) Substance Abuse  (4) Systemic Inflammatory Response Related Disorders  (161)    Inflammatory Pathophysiology  (9) Technology Transfer: Biotech and Pharmaceutical  (354) therapeutics  (3) Tissue Engineering and Regenerative Medicine  (22) Tissue Microenvironment  (5) Transarterial Chemoembolization  (2) Transcriptomics  (47) Transformative Technologies in Healthcare  (23) Translational Science  (230)    Best evidence  (52)    Bias measurement tools  (2)    Evidence-based decision-making  (29)    Inferential analysis  (25)    Intra-rater error  (1)    Quality Assurance  (8)    Random Error  (2)    Systematic Error (Bias)  (6)    Total error  (2)    Translational Effectiveness  (49)    Translational Research  (92) Trends in Global Economy  (6) Uncategorized  (1,019) Unfolded Protein Response (UPR)  (6) US and Global Economy: Trends and Findings  (9) Venture Capital  (47)    Income Geographic Distribution  (3)    Institutional Capital Raised by Female Founders  (6) virology  (10) Vision  (7) Voices of Patients and Healthcare Providers  (22) Water Transporters  (8) Wearable Tech + Digital Health  (5) Anemia  (22) Neutropenia  (8) Neutrophilia  (9) Platelet count disorder  (9) Folate and B12  (7) Iron deficiency  (5) Myelodysplasia  (13) Myelofibrosis  (10)

• Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

• • 2012pharmaceutical
  • sjwilliamspa